Fluorodeoxyuridine causes bilomas after hepatic cryotherapy

✍ Scribed by Soon, Patsy S.; Glenn, Derek; Jorgensen, John; Morris, David L.

• Publisher: John Wiley and Sons
• Year: 1998
• Tongue: English
• Weight: 687 KB
• Volume: 69
• Category: Article
• ISSN: 0022-4790
• DOI: 10.1002/(sici)1096-9098(199809)69:1<45::aid-jso9>3.0.co;2-k

✦ Synopsis

Background and Objectives: Hepatic cryotherapy is a method of in situ cytodestruction used for unresectable liver tumours that can be combined with regional cytotoxic administration. We have used intra-arterial chemotherapy with 5-fluorouracil (5-FU) after hepatic cryotherapy but changed to 5-fluorodeoxyuridine (FUDR) because of the arterial toxicity of 5-FU. A new complication was seen. Methods: A retrospective case note study was performed of 130 patients who had undergone hepatic cryotherapy followed by regional chemotherapy at our centre. Seven patients received FUDR; 123 received 5-FU.

Results: Biloma at the cryotherapy sites was seen in three patients in the FUDR group; two other patients in this group had other types of hepatic collection. Our previous experience with intra-arterial 5-FU in 123 patients after hepatic cryotherapy showed no evidence of this syndrome. Conclusions: Intra-arterial FUDR should not be used after hepatic cryotherapy, at least during the immediate postoperative period.